Niagen Bioscience, Inc. current report, 04 December 2013

SEC Filing Summary: ChromaDex Corp. (8-K)

Business Context and Reporting Period

This Form 8-K was filed by ChromaDex Corp. on December 4, 2013. The report discloses a corporate presentation intended for use at the LD Micro Conference in Los Angeles, CA, held on the same date. The filing serves as a Regulation FD disclosure to ensure equal access to material non-public information.

Financial Metrics

The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document is a procedural filing to attach a presentation (Exhibit 99.1) rather than a financial statement.

Material Changes

No material changes to financial performance or operations are reported in this document. The filing solely announces the release of a corporate presentation.

Guidance, Outlook, and Risks

Management commentary, guidance, and risk factors are contained within the attached presentation (Exhibit 99.1), which is not included in the text of this filing. The filing explicitly states that the information in the presentation is furnished and not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor is it incorporated by reference into other documents.

Key Facts for Investor Verification

  • Verify the content of Exhibit 99.1 (the corporate presentation) for actual financial data and strategic outlook.
  • Note that the presentation is not legally "filed" and cannot be incorporated by reference into other SEC documents.
  • Confirm the date of the LD Micro Conference presentation was December 4, 2013.
  • Identify Frank L. Jaksch Jr. as the Chief Executive Officer who authorized the filing.